Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.

Trial Details

NCT ID
NCT06580002
Phase
PHASE2
Sponsor
University of California, Irvine
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Riluzole
  • Placebo
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311

Key Eligibility Criteria

  • Cohort-specific inclusion for male and female patients.
  • a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:
  • Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions.
  • Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →